Concomitant myeloproliferative and lymphoproliferative neoplasms, distinct progenitors: A case report and review of the literature
Autor: | Sónia Matos, Filipa Mousinho, Ana Paula Azevedo, José Manuel Pereira, Paula Sousa E. Santos, João Faro Viana, Fernando Lima, Raquel Lemos |
---|---|
Přispěvatelé: | Repositório da Universidade de Lisboa |
Rok vydání: | 2018 |
Předmět: |
Cancer Research
Monoclonal B cell lymphocytosis Lymphocytosis Chronic lymphocytic leukemia Essential thrombocythemia Myeloproliferative neoplasms 03 medical and health sciences del(13q) 0302 clinical medicine hemic and lymphatic diseases Medicine Myeloproliferative neoplasm business.industry Cancer Articles medicine.disease JAK2V617F mutation Oncology Lymphoproliferative neoplasms 030220 oncology & carcinogenesis Concomitant Immunology Monoclonal Monoclonal B-cell lymphocytosis medicine.symptom business 030215 immunology |
Zdroj: | Repositório Científico de Acesso Aberto de Portugal Repositório Científico de Acesso Aberto de Portugal (RCAAP) instacron:RCAAP |
ISSN: | 2049-9469 2049-9450 |
DOI: | 10.3892/mco.2018.1682 |
Popis: | Copyright © 2018 Spandidos Publications. All rights reserved. Patients with a Philadelphia chromosome-negative myeloproliferative neoplasm may develop a lymphoproliferative disorder; however, the clinical and molecular determinants and the chronological onset of the two events remain unknown. We herein report the case of a 64-year-old man with concomitant diagnosis of high-risk essential thrombocythemia with evidence of a thrombotic event and high-count monoclonal B-cell lymphocytosis (high-count MBL). The patient harbored a JAK2V617F mutation and one of the most common genetic alterations found in chronic lymphocytic leukemia (CLL) (del 13q), which may represent a sign of disease progression. He was initiated on cytoreductive therapy with hydroxyurea 500 mg 3 times per week and hypocoagulation treatment, and is currently under regular surveillance of MBL without CLL criteria. |
Databáze: | OpenAIRE |
Externí odkaz: |